IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Bayer Australia is a Public Company that generates the majority of its income from the Pharmaceutical Product Manufacturing industry. In 2024 the company generated total revenue of $659,810,000 including sales and other revenue. In 2024 Bayer Australia had 94,081 employees including employees from all subsidiaries under the company's control. The Chief Executive of Bayer Australia is Mr Manoj Saxena whose official title is Group Chief Executive Officer Bayer ANZ. The Chairman of Bayer Australia is either not applicable or not available. Bayer Australia operates through three main divisions: Pharmaceuticals: Manufactures, markets, and conducts research on prescription drugs for the therapeutic areas of cardiology, oncology, gynaecology, hematology and ophthalmology. Consumer Health: Manufactures, markets, and conducts research on over-the-counter products. Crop Science: Manufactures, markets, and conducts research on seeds, crop protection and non-agricultural pest control products.The company offers products including, but not limited to, the following: Adempas Chipco GT Fungicide Drixine Indemnify Nematicide Menevit Polaramine Rennie Ultravist Yasmin
Answer any industry question in minutes with our entire database at your fingertips.
Feed trusted, human-driven industry intelligence straight into your platform.
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
IBISWorld's research coverage on the Bayer Australia Ltd includes market sizing, forecasting, data and analysis. The most recent publication will be as current as of March 2026.
Bayer Australia Ltd, trading as Bayer Australia, operates under the ABN 22 000 138 714 and was incorporated on 23 August 1954. Bayer Australia Ltd trades on the Australian Securities Exchange under the ticker code ASX:. Bayer Australia Ltd primarily operates in the Pharmaceuticals Wholesaling industry in Australia.
The Key Personnel chapter outlines the principal leadership positions within Bayer Australia Ltd, including the Chairman, Board members, Chief Executive Officer, and other key management personnel. It provides an overview of the company’s governance and executive structure, along with a breakdown of gender diversity across leadership roles, offering insight into the composition of the organisation’s senior team.
The Financials chapter presents Bayer Australia Ltd’s historical financial performance, including detailed profit and loss statements outlining sales revenue, cost of sales, and profitability. It also incorporates balance sheet data, providing a breakdown of assets and liabilities, as well as additional financial metrics such as the number of shares on issue. Together, these disclosures offer a comprehensive view of the company’s financial position and performance over time.
The Growth & Ratios chapter provides historical data on key financial performance indicators, enabling an assessment of the company’s operational efficiency, profitability, and financial structure over time. Metrics covered include return on equity, return on assets, profit margins, revenue per employee, as well as gearing and leverage ratios, offering a comprehensive view of performance trends and capital management.
The Operating Segments chapter provides an overview of the revenue composition and asset allocation across the various industries in which Bayer Australia Ltd operates. It offers insights into how the company’s financial performance is distributed among its core business segments, highlighting the relative contribution of each industry to total revenue.
The Competitor Benchmarking chapter includes a comparative assessment of Bayer Australia Ltd’s key financial, growth, and valuation ratios against industry averages to evaluate its competitive position. It analyses valuation metrics such as price-to-earnings, price-to-book, enterprise value to EBITDA, and enterprise value to sales, alongside core financial indicators including liquidity ratios and profitability measures.
The Industries of Operation chapter outlines Bayer Australia Ltd’s market share across the industries in which it operates. Each industry profile includes a comprehensive overview featuring data on total market size, the number of enterprises, industry concentration levels, and overall turnover. This analysis provides context for the company’s competitive position and scale within each relevant market.
The Shareholders chapter provides a breakdown of the ownership structure of Bayer Australia Ltd, identifying key shareholders and outlining their respective ownership interests. This section offers insight into the concentration of shareholdings, the presence of institutional or strategic investors, and the overall distribution of equity within the company.
The Subsidiaries chapter provides an overview of the companies and business entities that are wholly or partially owned by Bayer Australia Ltd. It outlines the ownership structure of each subsidiary, offering insight into the broader corporate group and how these entities contribute to the company’s overall activities and performance.
The History chapter presents a overview of Bayer Australia Ltd’s development, highlighting key milestones and significant corporate events since its incorporation. It includes the company’s incorporation date and outlines major strategic, operational, and structural developments, providing context for its evolution and current market position.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
Bayer Australia operates through three main divisions: Pharmaceuticals: Manufactures, markets, and conducts research on prescription drugs for the therapeutic areas of cardiology, oncology, gynaecology, hematology and ophthalmology. Consumer Health: Manufactures, markets, and conducts research on over-the-counter products. Crop Science: Manufactures, markets, and conducts research on seeds, crop protection and non-agricultural pest control products.The company offers products including, but not limited to, the following: Adempas Chipco GT Fungicide Drixine Indemnify Nematicide Menevit Polaramine Rennie Ultravist Yasmin
Bayer Australia Ltd, trading as Bayer Australia, is a Public Company that generates the majority of its income from the Pharmaceuticals Wholesaling industry in Australia.
Murray Cod Australia Limited company is based at 875 Pacific Highway, Pymble, New South Wales, Australia.
The Group Chief Executive Officer Bayer ANZ of Bayer Australia Ltd is Not Available and the Group Chief Executive Officer Bayer ANZ is Manoj Saxena.
In 2025, Bayer Australia Ltd generated total revenue of approximately $659.8 million.